Protalix BioTherapeutics' CEO to present at H.C. Wainwright conference.

Protalix BioTherapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025. CEO Dror Bashan will present at 3:30 p.m. Eastern Daylight Time in the Holmes II Room, Fourth Floor. Management will also participate in one-on-one meetings with registered investors.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled to take place from September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City. The biopharmaceutical company, known for its proprietary plant cell-based protein expression system ProCellEx, will be represented by Dror Bashan, the company's President and Chief Executive Officer. Bashan will deliver a presentation on Monday, September 8, at 3:30 p.m. Eastern Daylight Time (EDT) in the Holmes II Room, Fourth Floor. Additionally, the management team will engage in one-on-one meetings with registered investors throughout the conference [1].

Protalix BioTherapeutics specializes in the development and commercialization of recombinant therapeutic proteins using its unique plant cell-based expression system. The company is the first to gain U.S. Food and Drug Administration (FDA) approval for a protein produced through plant cell-based in suspension expression. Protalix has licensed the rights to Pfizer Inc. for the global development and commercialization of taliglucerase alfa, a protein for the treatment of Gaucher disease. The company's second product, Elfabrio, was approved by both the FDA and the European Medicines Agency in May 2023 [1].

The company's development pipeline includes several proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets. These include PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases [1].

This presentation at the H.C. Wainwright Annual Global Investment Conference provides an opportunity for investors and financial professionals to gain insights into Protalix BioTherapeutics' current status, future prospects, and pipeline developments.

References:
[1] https://www.marketscreener.com/news/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7c50d3dc8df42d